BMS-986504 Phase 1 Trial for Unresectable MPNST
ClinicalTrials.gov Studies
Summary
A Phase 1 clinical trial evaluating the safety and efficacy of BMS-986504 in patients with unresectable Malignant Peripheral Nerve Sheath Tumor (MPNST) has been registered on ClinicalTrials.gov under identifier NCT07549022. The study targets patients whose tumors exhibit MTAP (Methylthioadenosine Phosphorylase) loss, a genetic mutation hypothesized to increase the drug's ability to kill cancer cells. BMS-986504 is an investigational agent not yet approved by the FDA for any indication, and enrollment is limited to individuals with documented MTAP-deficient tumors.
“The purpose of this study is to see if a new medicine called BMS-986504 may work better than other available medicines for people with MPNST.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov registry entry adds a Phase 1 study (NCT07549022) evaluating BMS-986504 in patients with unresectable Malignant Peripheral Nerve Sheath Tumor. The trial focuses on participants whose tumors exhibit MTAP loss, a mutation theorized to sensitize cancer cells to the investigational treatment. The study drug is explicitly experimental and not FDA-approved for determining anti-tumor activity.
For pharmaceutical companies and clinical investigators, this registration signals active recruitment for an early-stage oncology compound targeting a rare tumor type. Patients and advocacy organizations focused on MPNST gain visibility into an additional trial pathway. No compliance obligations are created by this registry entry.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
Phase 1 NCT07549022 Kind: PHASE1 Apr 23, 2026
Abstract
People who have a cancer called MPNST, or Malignant Peripheral Nerve Sheath Tumor, may be eligible for this study. The purpose of this study is to see if a new medicine called BMS-986504 may work better than other available medicines for people with MPNST. Methylthioadenosine Phosphorylase (MTAP) loss is a gene mutation that some people have. MTAP loss seems to increase the chance that BMS-986504 can kill MPNST cancer cells. People who are missing MTAP from their tumor may be able to enroll in this study. Treating MPNST based on MTAP loss is considered experimental and is not approved by the US Food and Drug Administration (FDA) for determining whether BMS-98650 will be active against cancer. The purpose of this study is to evaluate the safety and effectiveness of BMS-986504 in participants with MPNST.
Conditions: Malignant Peripheral Nerve Sheath Tumors, MPNST
Interventions: BMS-986504
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.